Skip to content

Change in AP at other companies

Amgen logo
AmgenAMGN
$571M+14.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$107.7M+150%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$1.51M-9.1%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$911K-2.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$17.82M+25.9%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$219K-45.0%

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s change in AP?
Upstream Bio, Inc. (UPB) reported change in AP of -$1.02M in Q1 2026.
How has Upstream Bio, Inc.'s change in AP changed year-over-year?
Upstream Bio, Inc.'s change in AP decreased by 242.9% year-over-year, from $711K to -$1.02M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.